Has Rebecca Luebbert, PA received payments from drug or device companies?

Yes. Drug and device makers reported $2,092 in general payments to Rebecca Luebbert, PA across 62 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rebecca Luebbert, PA did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rebecca Luebbert, PA come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rebecca Luebbert, PA

Medical · Post Falls, IDNPI 1770061152

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,382 of the $2,092 with a category attached, or 66.0%. 26 manufacturers reported payments, led by Axonics, Inc. at 55.5% of the total. Reporting peaked in 2023 at $1,074 and has fallen 84.4% since, to $168 in 2025.

$2,092in general payments, 2019–2025

Across 62 payments — averaging $33.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Axonics, Inc.$1K
Astellas Pharma US Inc$111
Medtronic$106
Pfizer$99
Takeda Pharmaceuticals U.S.A., Inc.$77
180 Medical, Inc.$55
plus $482 from 20 others

What the payments were for

Travel & lodging$71134%
Food & beverage$1,38266%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Axonics, Inc.	13	$1,162
Astellas Pharma US Inc	4	$111
Medtronic	3	$106
Pfizer	5	$99
Takeda Pharmaceuticals U.S.A., Inc.	3	$77
180 Medical, Inc.	3	$55
Urogen Pharma, Inc.	4	$53
Coloplast	3	$44
Tolmar Pharmaceuticals, Inc.	2	$36
Tolmar, Inc.	2	$36
Telix Pharmaceuticals	2	$35
AbbVie	2	$34
Boston Scientific	2	$32
Progenics Pharmaceuticals, Inc.	2	$31
Dendreon Pharmaceuticals LLC	1	$19
Myovant Sciences Inc.	1	$17
Ferring Pharmaceuticals Inc.	1	$17
Rochester Medical Corporation	1	$17
Photocure Inc	1	$16
Johnson & Johnson	1	$16
Merck	1	$15
AstraZeneca	1	$14
Bayer	1	$14
Endo USA, Inc.	1	$13
Travere Therapeutics, Inc.	1	$13
Amgen	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Axonics$744
Axonics r-SNM System$104

How this compares

$2,092 in reported general payments places this provider in the 80th percentile of 265 medical providers in Idaho.

See all medical providers in Idaho →

Medicare billing

Part B allowed, 2024

$54,230

Medicare patients

220

Services billed

2,798

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
MyrbetriqMirabegron	63	$36,321
GemtesaVibegron	49	$26,869
Trospium Chloride ErTrospium Chloride	33	$4,542
Tamsulosin Hcl	368	$4,483
Oxybutynin Chloride ErOxybutynin Chloride	80	$1,761
Estradiol	21	$1,628
Finasteride	100	$1,240
Testosterone Cypionate	28	$1,110
Solifenacin Succinate	43	$876
Dutasteride	37	$785
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst	17	$323
Doxazosin Mesylate	11	$73

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Astellas Pharma US IncMyrbetriq	$111	$36,32163 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 265 medical providers in Idaho.